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ABSTRACT
Objectives: Characterize patients with diabetes with
severe hypoglycemia requiring emergency services
intervention at home and investigate 12-month
mortality.
Research design and methods: Emergency
services call-outs for hypoglycemia were recorded
between 2005 and 2013 in an area covering 34 000
patients with diabetes. Patient characteristics were
documented together with capillary blood glucose
(CBG), glycated hemoglobin (HbA1c), and treatment
for hypoglycemia; 12-month mortality and variables
influencing survival were analyzed.
Results: In 1835 episodes among 1156 patients, 45%
had type 1 diabetes (68.2% males) and 44% had type 2
diabetes (49.4% males), with a minority unclassified.
CBG at presentation (mean±SD) was 1.76±0.72 mmol/L
in patients with type 1 diabetes and 1.96±0.68 mmol/L
in patients with type 2 diabetes (p<0.0001), with a
higher HbA1c in the former group (8.3±1.52% (67.5
±16.4 mmol/mol) and 7.8±1.74% (61.6±19.0 mmol/
mol), respectively; p<0.0001). A third of patients with
type 2 diabetes were not on insulin therapy and
displayed lower HbA1c compared with insulin users.
Glucagon was used in 37% of patients with type 1
diabetes and 28% of patients with type 2 diabetes
(p<0.0001). One-year mortality was 4.45% in type 1
diabetes and 22.1% in type 2 diabetes. Age and type of
diabetes were predictive of mortality in multivariable
analysis, whereas CBG levels/frequency of
hypoglycemia had no effect.
Conclusions: Severe hypoglycemia in the community
is common with a male predominance in type 1
diabetes. Severe hypoglycemia in non-insulin treated
patients with type 2 diabetes is associated with lower
HbA1c compared with insulin users. Severe
hypoglycemia appears to be associated with increased
mortality at 12 months, particularly in type 2 diabetes.
INTRODUCTION
Hypoglycemia is a common side effect of
glucose-lowering treatment in diabetes melli-
tus (DM) and may have serious clinical con-
sequences in the short and long terms.1
Many episodes of hypoglycemia, even severe,
are managed at home by the patient or carer
and rarely require intervention of the ambu-
lance services or admission to hospital.
Severe hypoglycemia in diabetes, defined
as an episode requiring external assistance,
causes a significant burden on patients and
medical staff. Although most episodes of
hypoglycemia are managed by the patient or
family members/carers, studies estimate inci-
dence rates of 11.5 and 11.8 per 100 patient
years that require emergency medical service
intervention in type 1 diabetes and insulin-
treated type 2 diabetes, respectively.2 Severe
hypoglycemia was previously thought to be
predominantly related to insulin therapy, but
more recent work indicates that this occurs
with oral hypoglycemia agents (OHAs),
largely involving agents in the sulfonylurea
group.2–4 A recent meta-analysis has shown
that almost a fifth of patients on sulfonylurea
suffer at least one hypoglycemic episode,
with the risk of low blood glucose increasing
more than threefold with the use of these
agents.5 Although the incidence of severe
hypoglycemia is relatively low at 1.2%, the
Key messages
▪ Severe hypoglycemia in the community is
common, and presents a large burden on both
patients and healthcare workers.
▪ Using a large database of ambulance call-outs
for hypoglycemia, this study aimed to character-
ize those requiring the emergency services for
an episode of hypoglycemia, and to investigate
factors that may be associated with an increased
risk of mortality.
▪ We found that a third of patients with type 2 dia-
betes having severe hypoglycemic episodes were
not using any insulin; these individuals had a
lower glycated hemoglobin than those with type
2 diabetes requiring insulin treatment.
▪ Twelve month mortality following an episode of
severe hypoglycemia was high, especially in indi-
viduals with type 2 diabetes. More research is
required to investigate the cause of death in
these patients.
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large number of patients treated with sulfonylurea trans-
lates clinically into a significant number of individuals
suffering this serious complication.
Tight control of the blood glucose level in DM
reduces the risk of developing microvascular complica-
tions, but the effect on macrovascular disease is less
clear, at least in the medium term.6–12 Intensive glycemic
treatment carries an increased incidence of hypogly-
cemia, which is associated with increased mortality,
including cardiovascular death.8 13–18 Two large trials
investigating the role of intensive treatment in patients
with type 2 diabetes demonstrated that having one or
more episodes of severe hypoglycemia is associated with
increased mortality.8 9 18 Recent retrospective studies
have also found an increased mortality rate associated
with hypoglycemia in diabetes, in hospital and commu-
nity settings.19–21 It should be stressed that the associ-
ation between hypoglycemia and mortality does not
necessarily indicate causation. Low blood glucose may
be a marker of morbidity and frailty; however, the results
of a large recent meta-analysis suggest that this would
not entirely explain the association.22
Although large studies attempt to reduce bias and risk
of confounding, the randomized nature of a number of
such studies and the selected population investigated are
major caveats, making general applicability of the results
uncertain. Therefore, more work is needed to clarify the
relationship between hypoglycemia and mortality in the
diabetes population in real-life situations. In particular,
the characteristics of patients prone to severe hypogly-
cemia are not entirely clear and factors that may contrib-
ute to mortality following hypoglycemia require further
analysis.
The current study therefore aimed to: (1) characterize
a large cohort of patients with diabetes with severe hypo-
glycemia requiring emergency services intervention
while at home, (2) investigate mortality at 12 months fol-
lowing severe hypoglycemia and analyze the contribut-
ing factors to identify the subpopulation at risk.
METHODS
Study population and collection of basic data
Data have been collected on an emergency services
call-out for hypoglycemia between July 2005 and April
2013 by the project coordinator among a population of
approximately 34 000 participants with diabetes.
Individuals were included in the analysis if capillary
blood glucose (CBG) levels were less than 4 mmol/L at
attendance of the emergency crew. Basic characteristics
were collected by the Yorkshire Ambulance Services
(YAS) at the time of the episode, including basic patient
demographics (age, gender and type of diabetes).
Diabetes treatment was also recorded including pre-
scribed OHA and/or insulin therapy. CBG was mea-
sured at the arrival of ambulance services and following
treatment of hypoglycemia. Low blood glucose in these
individuals was treated by food/drink, glucagon, and/or
intravenous dextrose. Data on whether the individual
required transport to hospital were also collected. In a
minority of patients when the type of diabetes was
unknown, patients less than 30 years and using insulin
were assumed to have type 1 diabetes and patients using
one or more oral OHA(s) were assumed to have type 2
diabetes. All data were thoroughly examined for indivi-
duals with multiple episodes, which were clarified from
the database. Patients gave consent for referral into the
pathway which aimed for a diabetes specialist nurse to
contact the patient by phone within 5 days of the hypo-
glycemic episode to try to establish a cause and offer
advice to prevent further episodes.
The latest glycated hemoglobin (HbA1c) data before
the incident were recorded by the diabetes nurse spe-
cialist as part of the hypoglycemia pathway before anon-
ymized patient data, including pretreatment CBG and
treatment received, were passed to the research team.
Permission to undertake the study was given by the local
ethical authority.
Mortality data
A randomly selected 3-year sample was taken for mortal-
ity analysis (episodes between April 2009 and April
2012) after no statistically significant differences were
found between the 3-year sample and the whole data set
in regard to the gender distribution, the type of dia-
betes, mean age, mean pretreatment blood glucose and
whether patients were transported to the hospital. Data
concerning 1 year mortality following the last recorded
hypoglycemic episode were collected using a coding
system in the local database and date of death was
recorded. We were unable to locate the mortality status
of 11 patients; they were therefore excluded from the
analysis.
Procedures and statistical analyses
We used SPSS (V.22.0) for statistical analyses. Normally
distributed data are displayed as means and SDs, unless
otherwise stated, and were analyzed using a two-tailed
t test. Non-normally distributed data are displayed as
median and IQR, with the Mann-Whitney U test used to
assess differences. Categorical data were analyzed using
the χ2 test. Binary logistic regression was used to analyze
variables influencing 12-month mortality. In all tests, a
p value of less than 0.05 was considered to be
significant.
Multivariable analysis was used to analyze variables
influencing 12-month mortality. Variables included in
the model were: age, type of DM, whether they were
taken to hospital after initial treatment at the scene, the
number of episodes each patient had during the study
period, and their pretreatment CBG on their last
recorded episode. Logistic regression analysis was used
to identify predictors of 12-month mortality, and Cox
proportional regression models to perform survival ana-
lysis. For patients who were alive after 1 year from their
hypoglycemia, a 12-month census date was used,
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A total of 1911 episodes were recorded by the project
coordinator in 1195 patients, of which 76 were excluded
for the following reasons: multiple counting (n=14), ges-
tational diabetes (n=1), no history of diabetes (n=3) and
baseline CBG ≥4 mmol/L (n=58), as summarized in
figure 1. The remaining 1835 episodes occurred among
1156 patients, of which 520 (45%) had type 1 diabetes
and 503 (44%) had type 2 diabetes, with the rest of the
patients unclassified (11%). Of these individuals, 880
(76%) patients had a single hypoglycemic event com-
pared with 276 (24%) who had multiple hypoglycemic
episodes during the study period. The main character-
istics of patients are summarized in table 1.
Overall, a pretreatment CBG of less than 3.0 mmol/L
was found in 1643 (90%) episodes with approximately
80% of episodes recording a CBG of less than
2.5 mmol/L.
Blood glucose levels and HbA1c
The mean (±SD) pretreatment CBG in individuals with
type 1 diabetes was significantly lower than that in indivi-
duals with type 2 diabetes (1.76±0.72 vs 1.96
±0.68 mmol/L, respectively; p<0.0001). The reverse was
true for HbA1c with a mean of 8.3±1.52% (67.5
±16.4 mmol/mol) in type 1 diabetes compared with 7.8
±1.74% (61.6±19.0 mmol/mol) for type 2 diabetes
(p<0.0001). When comparing HbA1c between genders
in type 1 diabetes, a mean of 8.3±1.41% (67.4
±15.1 mmol/mol) was found in males, which was similar
to females at 8.3±1.82% (67.7±19.3 mmol/mol; p=0.86).
Treatment for hypoglycemia
This included: food and drink (including the use of
glucose gel), intravenous glucose, intramuscular gluca-
gon or none. Episodes in which food and drink were
given had a significantly (p<0.0001) higher mean pre-
treatment CBG (2.21±0.73 mmol/L) compared to those
in which glucagon (1.61±0.60 mmol/L) or intravenous
glucose (1.67±0.63 mmol/L) were used. Details of hypo-
glycemic treatment are provided in table 1. There was
marginally higher glucose levels post-treatment in
patients with type 1 diabetes compared with those with
type 2 diabetes (6.41±2.71 vs 6.15±2.59 mmol/L, respect-
ively; p=0.049). There was no difference in the type of
treatment administered for hypoglycemia when compar-
ing patients with type 2 diabetes on insulin with those
using OHAs alone.
Transport to hospital
Of all episodes, 123 (7%) were subsequently transported
to hospital. Those transported were older (median age
71 years (51–80) vs 60 (43–74), p=0.0017), more likely to
have type 2 diabetes than type 1 diabetes (9% vs 4%,
respectively; p=0.0001), lived alone (37% vs 24%,
respectively; p=0.0012), and were more likely to have
had just one episode compared to multiple previous epi-
sodes (67% vs 33%, respectively; p<0.0001).
Insulin and non-insulin-treated patients with type 2
diabetes
Two-thirds of individuals with type 2 diabetes (69%)
were on insulin treatment, and this group included
those having insulin alone or in combination with
OHA(s). Among 2% of episodes, the treatment type
remained unknown, but the remaining 29% were on
OHA alone. Within the subset using solely OHAs, 159
episodes (82%) involved a sulfonylurea either independ-
ently or in conjunction with one or more OHA. Only
3% of episodes occurred with OHA not usually asso-
ciated with hypoglycemia, including metformin. In 30 of
the remaining episodes (15%), the type of OHA used
was unknown, and therefore sulfonylurea use may have
been even higher. Individuals with type 2 diabetes on
OHA treatment alone had a significantly lower HbA1c
compared with insulin users (see table 2; 7.0±1.66% (53
±18.0 mmol/mol) vs 8.3±1.56% (67±17.0 mmol/mol),
respectively; p<0.0001.
Outcome 1 year following hypoglycemia
Given the uniformity of data, we conducted 12-month
mortality analysis in a 3-year sample taken between April
2009 and April 2012 (739 episodes in 510 patients). The
characteristics of these patients were similar to those of
the study group as a whole (data not shown). Of these
510 patients, 67 died within a year, giving a 12-month
mortality rate of 13.1%. The median age of patients who
died within a year of their last recorded episode was
77 years (72–82). There were 10 patients who had died
within a year who had an unknown type of diabetes.
There were a total of 11 patients (6 male, 5 female)
with type 1 diabetes who were found to have died 1 year
after their last presentation, giving a 12-month mortality
rate of 4.45% with a median age of 54 (43–67) years.
Figure 1 Flow diagram showing episodes excluded from
data analysis. CBG=capillary blood glucose.
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There were 46 patients (23 male, 23 female) with type
2 diabetes who had died within a year, giving a
12-month mortality rate of 22.1% with a median age of
78 (74–82) years. There was no significant difference in
mortality rates as to whether patients with type 2 dia-
betes were on insulin or non-insulin therapy for the
management of glycemia (data not shown). Of the 67
patients who died 12 months after their last episode,
38.8% (n=26) of these deaths occurred in the first
3 months (giving a 3-month mortality rate of 5.1%).
Excluding patients with type 2 diabetes with an age
≥75 years, which gave a median age of 67 years (60–72),
12-month mortality fell to 14.3%. The mortality rate of
those patients with type 2 diabetes aged ≥75 years was
27.4% (median age 81 years, IQR 78–84).
Predictors of mortality
A model was used to find significant predictive variables
for 12-month mortality, which included age, type of dia-
betes, transport to hospital after the episode, pretreat-
ment blood glucose and multiple episodes within the
past 3 years.
In univariate analysis, age and type of diabetes were
predictors of mortality with ORs of 1.056 (1.036 to
1.077) and 6.092 (3.063 to 12.116), respectively.
Transport to hospital only showed a trend, whereas sever-
ity of hypoglycemia or number of episodes showed no
predictive value (see table 3). Multivariate analysis
yielded similar data, with the effect of age and type of
diabetes on mortality not confounded by other
variables.
Survival analysis
Survival analysis was completed using a Cox proportional
hazards model to further investigate the effect of differ-
ent variables on mortality. Results of survival analysis
were consistent with logistic regression, with age (HR
1.025 (1.006 to 1.045), p=0.011) and having type 2 dia-
betes (HR 2.034 (1.016 to 4.072), p=0.045) remaining
significantly associated with an increased risk of death.
CONCLUSIONS
This is the largest study to investigate, over a period of
8 years, the main characteristics of patients with diabetes







Median age (years) 61 (44–75) 48 (35–61) 75 (68–81) <0.0001
Females (%) 732 (40%) 323 (32%) 336 (51%) <0.0001
Pretreatment CBG (mmol/L) 1.85 (±0.72) 1.76 (±0.72) 1.96 (±0.68) <0.0001
Post-treatment CBG (mmol/L) 6.30 (±2.66) 6.41 (±2.71) 6.15 (±2.59) 0.0494
Mean HbA1c (mmol/mol) 65.0 (±17.8) 67.5 (±16.4) 61.6 (±19.0) <0.0001
Insulin use 1600 (87%) 1015 (100%) 448 (69%)
Treatment given
Food and drink 640 (35%) 314 (31%) 272 (41%) <0.001
IV Glucose 531 (29%) 294 (29%) 187 (28%) 0.722
Glucagon 609 (33%) 379 (37%) 187 (28%) <0.001
None 22 (1%) 14 (1%) 6 (1%) 0.38
Transported to hospital 123 (7%) 40 (4%) 59 (9%) 0.0018
Lives alone 463 (25%) 221 (21%) 199 (30%) <0.0001
Data are presented as absolute numbers (percentages), median (IQR) or mean (SD).
CBG, capillary blood glucose; HbA1c, glycated hemoglobin; IV, intravenous; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
Table 2 Characteristics of episodes among those with type 2 diabetes by treatment modality
Insulin with or without OHA OHA alone Not known p Value
Episodes 458 (69%) 195 (29%) 11 (2%) <0.001
Pretreatment CBG (mmol/L) 1.91 (±0.70) 2.06 (±0.64) 0.0113
Post-treatment CBG (mmol/L) 6.22 (±2.63) 6.00 (±2.56) 0.3220
OHA use 48 (10.5%)
Sulfonylurea (alone and in combo) 14 (3%) 159 (82%)
Metformin alone 26 (6%) 5 (2.5%)
Pioglitazone alone 0 1 (0.5%)
Unknown 5 (1%) 30 (15%)
Other 3 (0.5%) 0
Mean HbA1c (mmol/mol) 67.0 (±17.0) 53.0 (±18.0) <0.0001
CBG, capillary blood glucose, HbA1c, glycated hemoglobin; OHA, oral hypoglycemic agent.
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who develop severe hypoglycemia in the community
requiring emergency services intervention. Moreover,
this work analyzed mortality within 12 months of the
hypoglycemic episode, to further clarify the relationship
between low blood glucose and medium-term clinical
outcome.
Our study showed: (1) Patients with diabetes requiring
emergency services intervention for hypoglycemia were
approximately equally divided between patients with
type 1 diabetes and type 2 diabetes with more severe
hypoglycemia documented in the former group, (2)
gender distribution was similar in those with type 2 dia-
betes, but a male predominance was evident in type 1
diabetes, (3) treatment to reverse hypoglycemia was dif-
ferent comparing type 1 diabetes with type 2 diabetes,
with a more frequent use of glucagon in the former
group, (4) a third of patients with type 2 diabetes were
not on insulin treatment and had a lower HbA1c com-
pared with the insulin-treated group, (5) mortality was
high within 12 months of the hypoglycemic event, par-
ticularly in participants with type 2 diabetes.
The severity of hypoglycemia requiring emergency ser-
vices intervention appeared more profound in indivi-
duals with type 1 diabetes compared with those with
type 2 diabetes. This may be due to the former group
being more able to treat mild hypoglycemia at home
without emergency services input, or it may relate to
impaired defences against hypoglycemia in those with
type 1 diabetes. In support of the former theory, a study
in 2005 demonstrated that among people with type 1
diabetes, the majority of episodes of severe hypogly-
caemia were treated by friends or relatives and did not
require emergency service intervention.23 Hence, those
episodes in which emergency service help was sought
are presumably the most severe as the individuals’
normal treatment measures at home had failed. The
more severe hypoglycemia in type 1 diabetes led to dif-
ferent treatment strategies to reverse low blood sugar,
including the use of intravenous glucose and glucagon.
This, in turn, may explain the higher post-treatment
glucose levels in this group. Another explanation is
related to the treatment administered, as OHAs have a
more sustained glucose-lowering effect compared with
insulin. However, the failure to detect a difference in
post-treatment glucose levels in insulin and non-insulin
users within the type 2 diabetes group argues against
this explanation. The bias toward a male gender distri-
bution in patients with type 1 diabetes was a consistent
and potentially interesting finding. Although we are
unable to provide a clear explanation for this observa-
tion, one possibility would have been related to gender
differences in glycemic control. However, this was ruled
out by demonstrating similar HbA1c in males and
females with type 1 diabetes. An alternative explanation
may be related to the recently documented link between
‘fear of hypoglycemia’ and female gender.24 25 It is pos-
sible that the enhanced fear of hypoglycemia in females
with type 1 diabetes results in more frequent glucose
testing, consequently ‘protecting’ from severe hypogly-
cemia that requires emergency services intervention.
Future work is required to systematically analyze the
reasons for this apparent gender difference.
In patients with type 2 diabetes, glucose levels in
insulin and non-insulin-treated participants at presenta-
tion were not that dissimilar, indicating that OHA can
induce severe hypoglycemia to a similar degree as
insulin. Not unexpectedly, the majority of OHA-treated
patients were on sulfonylurea therapy, which is an estab-
lished second-line therapy in diabetes due to the known
side effect profile and low cost. It should be noted that
no difference in treatment to reverse hypoglycemia was
observed in insulin and non-insulin-treated patients and
the rate of hospital transfer was similar in the two
groups. However, a clear difference was detected in
HbA1c with OHA-treated patients displaying significantly
lower levels of HbA1c compared with insulin users.
A major finding of this study was the high rate of mortal-
ity within a year of the hypoglycemic event, with a
12-month mortality rate of 13.1% and a 3-month mortality
rate of 5.1%. Although the observational nature of data
cannot provide evidence for causal relationship, the close
association between hypoglycemia and mortality requires
future investigation, as recent meta-analysis has shown that
confounding factors (such as severe illness) may not
explain the association alone.22 Mortality was particularly
pronounced in individuals with type 2 diabetes and was
similar to mortality following myocardial infarction in a
similar group of patients.26 Our data are consistent with a
recent study showing as association between hypoglycemia
and mortality in insulin-treated patients with diabetes who
Table 3 Univariate and multivariate analysis of factors predicting mortality 12 months after the last hypoglycemic episode
recorded between April 2009 and April 2012
Univariate Multivariate
OR (95% CI) p Value OR (95% CI) p Value
Age 1.056 (1.036 to 1.077) <0.001 1.041 (1.014 to 1.069) 0.002
Type of diabetes (type 2 diabetes) 6.092 (3.063 to 12.116) <0.001 2.468 (1.025 to 5.944) 0.044
Transported after episode 1.935 (0.940 to 3.984) 0.073 2.276 (0.995 to 5.207) 0.052
Pretreatment CBG 0.961 (0679 to 1.362) 0.824 0.691 (0.440 to 1.086) 0.109
>1 episode 1.161 (0.619 to 2.178) 0.641 0.747 (0.352 to 1.584) 0.447
Data are presented as OR with 95% CIs.
CBG, capillary blood glucose.
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were older than 30 years.27 In contrast to our study,
however, the authors failed to assess mortality in those who
were not on insulin treatment.
The work has a number of strengths including the
real-life clinical setting, the relatively large cohort
studied, relatively good characterization of patients, and
the clear distinction between patients with type 1 dia-
betes and those with type 2 diabetes. This is the first
study to detail the treatment given and to demonstrate
differences in management of patients with type 1 dia-
betes and type 2 diabetes following severe hypoglycemia
and also differences in mortality.
However, there are a number of limitations to this
study that need to be acknowledged. First, some ambu-
lance call-outs may not have been captured, as only
patients who have been recorded are analysed and
therefore our data may underestimate the size of the
problem. Second, some data were missing in a minority
of patients, a known disadvantage of such observational
studies. Third, the causes of death and various
comorbidities in these patients have not been documen-
ted in this work. For example, information regarding
comorbidities would help clarify the potential role of
hypoglycemia in mortality or may simply indicate that
low glucose levels are a marker of early demise in
patients with diabetes. Finally, there are known limita-
tions with the accuracy of CBG measurements as the
patients may have been hypoglycemic for different
periods of time before calling for an ambulance, and
the CBG meters can also be inaccurate, especially when
recording very low glucose readings. The use of the
CBG values does, however, confirm that all the episodes
included were genuine hypoglycemic events.
Given these limitations, a longitudinal prospective
study is required to further address these deficiencies,
which is currently ongoing.
In summary, our study shows that hypoglycemia in dia-
betes requiring emergency services intervention is
common with differences demonstrated between type 1
diabetes and type 2 diabetes in relation to gender distri-
bution, severity of hypoglycemia, type of treatment admi-
nistered, and postintervention glucose levels. A third of
patients with type 2 diabetes were not on insulin
therapy, being mainly treated with a sulfonylurea, and
some of these individuals had an inappropriately low
HbA1c. Mortality rate in patients with type 1 and type 2
diabetes was high following the hypoglycemic episode,
although a causative relationship is yet to be demon-
strated. Future work is needed to further investigate the
cause of death in these individuals and explore various
management strategies aiming to reduce the unaccept-
ably high mortality in this group of individuals.
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